Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
VTAK
Catheter Precision, Inc.
VIVO System involves medical imaging/mapping of the heart, aligning with Medical Imaging.
|
$2.43M |
$2.15
-3.15%
|
|
MHUA
Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies' core business is the manufacturing and sale of disposable medical device consumables.
|
$2.43M |
$7.62
+0.13%
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$2.34M |
$0.26
+1.98%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
BTCY
Biotricity, Inc.
Core cardiology device portfolio including 3-channel ECG monitoring platforms (Bioflux/Biocore/Biocore Pro).
|
$2.21M |
$0.24
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.02M |
$0.31
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.98M |
$1.79
-2.97%
|
|
MYNZ
Mainz Biomed B.V.
PancAlert is a blood-based diagnostic test using biomarker panels (liquid biopsy) to detect pancreatic cancer, fitting the Liquid Biopsy investable theme.
|
$1.96M |
$0.83
-1.67%
|
|
NAKA
Nakamoto Inc.
Provides patient-first healthcare services and operates clinics/delivery of care under KindlyMD.
|
$1.93M |
$0.27
+4.62%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$1.77M |
$0.01
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.70M |
$1.15
-4.58%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$1.66M |
$1.12
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.66M |
$3.20
-3.90%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$1.63M |
$0.19
-2.18%
|
|
AEMD
Aethlon Medical, Inc.
Hemopurifier is a blood purification device, the core product offering of Aethlon Medical.
|
$1.51M |
$2.00
+1.02%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$1.49M |
$0.11
+3.01%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
SIGY
Sigyn Therapeutics, Inc.
Sigyn Therapy is a broad-spectrum blood purification device designed to remove pathogens, toxins, and inflammatory mediators from blood.
|
$1.44M |
$0.08
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$1.34M |
$0.03
+4.00%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.31M |
$0.02
|
|
VYST
Vystar Corporation
RxAir medical-grade air purification devices and FDA-cleared units position the company in medical devices and biometrics.
|
$1.26M |
$0.06
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$1.18M |
$0.65
+18.18%
|
|
SOBR
SOBR Safe, Inc.
SOBR directly manufactures biometric-enabled medical devices (SOBRcheck) and wearable monitoring hardware (SOBRsure) paired with a cloud software platform.
|
$1.16M |
$0.68
-11.50%
|
|
WLDS
Wearable Devices Ltd.
Biometric authentication and biometric sensing features embedded in the Mudra platform align with Medical Devices & Biometrics.
|
$1.07M |
$1.47
+5.00%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$1.01M |
$0.68
-9.53%
|
|
AURX
Nuo Therapeutics, Inc.
Aurix System is a wound care device used for chronic wounds (direct product).
|
$972618 |
$1.50
|
|
SGBX
Safe & Green Holdings Corp.
Medical segment includes point-of-care solutions and the Sanitec disinfecting system, aligning with Medical Devices & Biometrics.
|
$845455 |
$1.74
-6.72%
|
|
INIS
Radnostix, Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$803238 |
$0.08
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$748811 |
$0.79
-67.61%
|
|
SSKN
STRATA Skin Sciences, Inc.
STRATA's core offerings are dermatology-focused excimer laser systems and related medical devices (XTRAC, Pharos lasers; VTRAC lamp systems; TheraClear X), which are medical devices and equipment.
|
$709097 |
$0.21
+33.65%
|
Showing page 37 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
